Latest Market Data
Refresh
Market Turnover
-






-
-
|
|
|
|
|
|
-
-
-
Loading

HANGZHOU TIGERMED CONSULTING CO., LTD. - H SHARES (3347)

TIGERMED (3347)

HK$50.250

+1.850 (+3.82%)

Prev. Close is the most recent non-zero closing value or settlement price.PREV. CLOSE
HK$48.400
Open price is the first traded price of the day. The opening price is reported after 09:20:00 HKT.OPEN
HK$49.400
TURNOVER
HK$157.02M
VOLUME
3.14M
MKT CAP
HK$6.18BH Shares only
LOT SIZE
100
BID
HK$50.150
ASK
HK$50.250
EPS
RMB0.4694
P/E
101.27x
DIV YIELD
0.65%
INTRA-DAY 52W
High HK$50.850 HK$58.800
Low HK$48.900 HK$22.300
Information is available after the market opens and is delayed by at least 15 minutes.
Updated: 24 Jul 2025 16:08 HKT
  • 1 D
  • 1 M
  • 3 M
  • 6 M
  • YTD
  • 1 Y
  • 2 Y
  • 5 Y
  • 10 Y
1min
5min
15min
Hourly
Created with Highstock 6.2.048.00048.80049.60050.40051.200060K120K10:0011:0012:0013:0014:0015:0016:00Prev. Close
48.400
All charts use the last traded price or closing price.

COMPANY PROFILE

Hangzhou Tigermed Consulting Co Ltd is a China-based holding company engaged in providing clinical trial services for research and development of new drugs. The Company operates two segments. The Clinical Trial Solutions segment provides clinical trial operation services and medical translation services to biopharmaceutical and medical device companies and thus help them conduct clinical trials of innovative drugs, generic drugs and medical devices. The Clinical-Related and Laboratory Services segment is involved in provision of analytical services, such as data management and statistical analysis; logistics and execution support services, such as clinical trial site management; administrative assistance, such as patient recruitment; as well as consulting services. This segment also provides laboratory services for preclinical and clinical development stages through its subsidiary. The Company conducts its businesses in the domestic and overseas markets. *
Please click to see notes of Issued Shares.Issued Shares (excluding treasury shares) 123,124,800 (as at 30 Jun 2025)
Industry Healthcare - Pharmaceuticals & Biotechnology - Biotechnology Industry Classification (HSIC) is provided by Hang Seng Indexes Company Limited. Please see the . (HSIC) Health Care Industry Classification (CSIC) is provided by China Securities Indexes Co., Ltd. and only available for companies dually listed in Hong Kong and Shanghai. Please see the . (CSIC)
Listing Date 7 Aug 2020
Financial Year Ends 31 Dec 2024
Chairman Ye Xiaoping
Principal Office Fl.15, Dongguan Plaza
No.618 Jiangnan Avenue
Binjiang District
Hangzhou, 310053, China
Place of Incorporation PRC
Listing Category Primary Listing

a. Updating time-lag
The number of issued shares / issued units presented is generally updated within 7 days after the Monthly Returns and Next Day Disclosure Returns published by the listed issuers on the HKEXnews website. Hence, the information presented here may not be the most up-to-date information submitted by the listed issuers as required under the Listing Rules.
b. Rights issues or bonus issues
The number of issued shares / issued units presented here will be adjusted with effect from the ex-date in the event of announced rights issues or announced bonus issues. In this case, both the number of issued shares / issued units before and after the adjustment will be presented.
c. Share splits or share consolidations
The number of issued shares / issued units presented here will be adjusted on the effective date in the event of share splits or share consolidations.
d. Conversion of convertible notes into shares
If the change of the number of issued shares / issued units is due to conversion of convertible bonds, the number of issued shares / issued units presented here may be updated based on the related company announcement.
Updated: 24 Jul 2025 18:24 HKT
* Company profile is provided by Refinitiv.

ENTITLEMENT

Date Announced Ex-Date Details Financial Year End Book Close Date Payment date may be indicative only.Payment Date
27 Mar 202512 Jun 2025Fin Div RMB 3.00 per 10 shs
(HKD 3.245 per 10 shs)
31 Dec 202416 Jun 2025 - 19 Jun 202511 Jul 2025
28 Aug 2024-No Dividend for the period ended
2024/06/30
31 Dec 2024--
28 Mar 202407 Jun 2024Fin Div RMB 5.68 per 10 shs
(HKD 6.2365 per 10 shs)
31 Dec 202312 Jun 2024 - 14 Jun 202418 Jul 2024
25 Aug 2023-No Dividend for the period ended
2023/06/30
31 Dec 2023--
28 Mar 202325 May 2023Fin Div RMB 5.50 per 10 shs
(HKD 6.1556 per 10 shs)
31 Dec 202230 May 2023 - 01 Jun 202307 Jul 2023
LOAD MORE
Updated: 25 Jul 2025 01:15 HKT
Dividend details are sourced from Announcement Forms published on HKEXnews